Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Stabilisation Notice

31 Mar 2015 15:27

RNS Number : 0377J
Citigroup Global Markets Limited
31 March 2015
 

31st March 2015

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Hikma Pharmaceuticals PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

Hikma Pharmaceuticals PLC

Guarantor (if any):

Aggregate nominal amount:

$ TBC

Description:

Reg S registered

Offer price:

TBC

Other offer terms

TBC

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

1st April 2015

Stabilisation period expected to end no later than:

1st May 2015 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJBMITMBTJBFA
Date   Source Headline
19th Apr 20164:14 pmRNSDirector/PDMR Shareholding
19th Apr 201612:57 pmRNSDirector/PDMR Shareholding
12th Apr 201610:02 amRNSDirector/PDMR Shareholding
8th Apr 20167:00 amRNSUpdate on ANDA for Generic Advair Diskus®
8th Apr 20167:00 amRNSPortfolio Update - VR315 US
7th Apr 20164:08 pmRNSDirector/PDMR Shareholding
7th Apr 201611:41 amRNSAnnual Information Update
7th Apr 201610:54 amRNSAnnual Financial Report
6th Apr 20164:11 pmRNSBlocklisting Interim Review
5th Apr 20164:13 pmRNSDirector/PDMR Shareholding
31st Mar 20165:37 pmRNSDirector/PDMR Shareholding
29th Mar 20169:36 amRNSDirector/PDMR Shareholding
21st Mar 20162:54 pmRNSDirector/PDMR Shareholding
17th Mar 20163:25 pmRNSDirector/PDMR Shareholding
16th Mar 20167:00 amRNSFinal Results
3rd Mar 20169:25 amRNSNotice of Results
29th Feb 20162:01 pmRNSHolding(s) in Company
29th Feb 20161:59 pmRNSHolding(s) in Company
29th Feb 20161:47 pmRNSTotal Voting Rights
29th Feb 20161:46 pmRNSRoxane Acquisition Close
22nd Feb 20169:52 amRNSDirectorate Change
19th Feb 201612:55 pmRNSEGM Statement
11th Feb 201612:43 pmRNSHolding(s) in Company
11th Feb 201612:19 pmRNSCirc re. Roxane Acquisition
10th Feb 201610:38 amRNSHikma Analyst and Investor Call
10th Feb 20167:00 amRNSCirc re. Roxane Acquisition
22nd Jan 20162:04 pmRNSCirc re. Roxane Acquisition and EGM
7th Jan 201611:08 amRNSTotal Voting Rights
24th Dec 20157:52 amRNSShareholders' Agreement and Board Appointment
17th Dec 20159:38 amRNSTotal Voting Rights
3rd Dec 20159:30 amRNSDirector/PDMR Shareholding
25th Nov 20158:45 amRNSHikma announces sale of Ben Venue manufacturing
24th Nov 20157:00 amRNSHolding(s) in Company
18th Nov 20157:00 amRNSResolution to FDA Warning Letter
16th Nov 20153:04 pmRNSHolding(s) in Company
11th Nov 20154:16 pmRNSHolding(s) in Company
10th Nov 20152:43 pmRNSHolding(s) in Company
2nd Nov 20157:00 amRNSTrading Statement
22nd Oct 20157:00 amRNSBlock Listing of Share
19th Oct 201511:11 amRNSHolding(s) in Company
12th Oct 201510:25 amRNSBlocklisting Interim Review
8th Oct 20154:10 pmRNSTotal Voting Rights
18th Sep 20152:40 pmRNSAudit Tender
16th Sep 20154:08 pmRNSTotal Voting Rights
11th Sep 20153:47 pmRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSHikma agrees to acquire EIMC United Pharmaceutical
27th Aug 20154:02 pmRNSDirector/PDMR Shareholding
27th Aug 20153:03 pmRNSDirector/PDMR Shareholding
19th Aug 20156:28 pmRNSDirector/PDMR Shareholding
19th Aug 20157:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.